Register Login

Zentalis Pharmaceuticals (ZNTL)

(10% Negative) ZENTALIS PHARMACEUTICALS, INC. (ZNTL) Announces Delay in pathway Trials for registration Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 10:20 p.m.

    📋 ZENTALIS PHARMACEUTICALS, INC. (ZNTL) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 17:18:32

    Event Type: Clinical Trial Update

    Event Details:

    Zentalis Pharmaceuticals (ZNTL) Announces Clinical Trial Update Zentalis Pharmaceuticals (ZNTL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: pathway, intended
    • Diseases/Conditions: registration, azenosertib
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: FDA
      • expected by year-end 2026
      • expected in 1H 2026
      • Anticipated by YE2026

    🔬 Clinical Development Pipeline (ZENTALIS PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    azenosertib DRUG Phase PHASE2 High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Zentalis Pharmaceuticals
    • CIK: 0001725160
    • Ticker Symbol: ZNTL
    • Period End Date: 2026-01-06
    • Document Type: 8-K

Search

News categories